Treatment of choroidal neovascularisation in highly myopic eyes
AbstractBackground: The aim of this study was to examine the effectiveness (visual outcome) of photodynamic therapy with verteporfin (PDT) and intravitreal anti-VEGF therapy for the treatment of choroidal neovascularisation secondary to pathologic myopia. Methods: A retrospective study of choroidal neovascularisation in highly myopic patients was undertaken at the Eye Hospital Ljubljana (from 2004 to 2010). The main outcome measures were: spherical equivalent, age at onset of CNV, composition and location of CNV, visual acuity before treatment, treatment type (PDT, intravitreal anti-VEGF injections, combination of both treatments), visual acuity after treatment and treatment-related complications. Results: Fifty-nine eyes of 59 patients (7 men and 52 women) with myopic CNV were enrolled in the study. The mean age of the patients was 59.7 (range 26–83) years and the spherical equivalent refractive error was – 10.2 D (range – 6.0 D to – 20.0 D). Twenty-four eyes were treated with PDT, 9 with PDT and anti-VEGF, and 26 eyes with anti-VEGF injections alone. The followup period was 21.5 months (range 6 months–6 years). The patients treated with anti-VEGF injections had a better final best-corrected visual acuity than PDT treated patients. No systemic side effects were noted. Conclusions: Intravitreal anti-VEGF injections are an effective therapy for sub- and juxtafoveal myopic CNV.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.